

MYLAN LABORATORIES INC

Form 8-K

August 18, 2004

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15 (d) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **August 17, 2004**

**MYLAN LABORATORIES INC.**  
(Exact name of registrant as specified in its charter)

<b>Pennsylvania</b> (State or other jurisdiction of incorporation)	<b>1-9114</b> (Commission File Number)	<b>25-1211621</b> (I.R.S. Employer Identification No.)
---	--	--

**1500 Corporate Drive  
Canonsburg, PA 15317**  
(Address of principal executive offices)

**(724) 514-1800**  
(Registrant's telephone number, including area code)

---

**Item 5. Other Events and Regulation FD Disclosure.**

On August 18, 2004, Mylan Laboratories Inc., a Pennsylvania corporation, issued a press release announcing an update in its fentanyl litigation pending in the U.S. District Court for the District of Columbia. A copy of the press release is attached hereto as Exhibit 99.1, and the court's August 17, 2004 opinion referred to in the release is attached as Exhibit 99.2.

**Item 7. Financial Statements and Exhibits.**

(c) Exhibits.

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release of the registrant, dated August 18, 2004.
99.2	Memorandum Opinion of the U.S. District Court for the District of Columbia, dated August 17, 2004.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MYLAN LABORATORIES INC.

Date: August 18, 2004

By: /s/ Edward J. Borkowski  
Edward J. Borkowski  
Chief Financial Officer

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release of the registrant, dated August 18, 2004.
99.2	Memorandum Opinion of the U.S. District Court for the District of Columbia, dated August 17, 2004.